← All diseases Brain and nervous system

Multiple sclerosis (progressive)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchEvidence of the highest level only (104)Meta-analysis (24)Treatment guideline (1)Randomized trial (43)Systematic review (21)Phase 3 Study (15)Clinical trial (370)Review article (234)Early study (phase 1 or 2) (22)Case report (83)Laboratory or animal study (21)Commentary or editorial (19) Studies currently recruiting participants only (33)

Filter

Publications and studies (1543)

• Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics. (2023/02/01) ♡
• Percutaneous revascularization for the treatment of refractory digital ischemia in systemic sclerosis. (2023/02/01) ♡
• Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis. (2023/02/01) ♡
• Participant Perspectives on Community Qigong for People with Multiple Sclerosis. (2023/02/01) ♡
• Mediterranean diet is linked to less objective disability in multiple sclerosis. (2023/02/01) ♡
• Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS). (2023/01/15) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Regionally restricted modulation of Sam68 expression and Arhgef9 alternative splicing in the hippocampus of a murine model of multiple sclerosis. (2023/01/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Oxidative stress in multiple sclerosis-Emerging imaging techniques. (2023/01/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sex, aging and immunity in multiple sclerosis and experimental autoimmune encephalomyelitis: An intriguing interaction. (2023/01/09) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms of Moringa oleifera. (2023/01/05) ♡
• Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. (2023/01/03) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Limb apraxia in individuals with multiple sclerosis: Is there a role of semi-immersive virtual reality in treating the Cinderella of neuropsychology? (2023/01/01) ♡
• Associations of sNfL with clinico-radiological measures in a large MS population. (2023/01/01) ♡
• Working memory dysfunction differs between secondary progressive and relapsing multiple sclerosis: Effects of clinical phenotype, age, disease duration, and disability. (2023/01/01) ♡
• Perivascular PDGFRB+ cells accompany lesion formation and clinical evolution differentially in two different EAE models. (2023/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The nine hole peg test as an outcome measure in progressive MS trials. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study. (2023/01/01) ♡
• Biomechanical changes of the common carotid artery and internal jugular vein in patients with multiple sclerosis. (2023/01/01) ♡
• Facial emotion impairment in multiple sclerosis is linked to modifying observation strategies of emotional faces. (2023/01/01) ♡
• Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden. (2023/01/01) ♡
• Evaluation of the relationship between the morphometric structure of the pituitary gland and fatigue in patients with multiple sclerosis. (2023/01/01) ♡
• Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis. (2023/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Effect of Acupuncture on Sensorimotor Function and Mobility in Patients with Multiple Sclerosis: A Pilot Study. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Development of the Combination Drug Leukovir(®) Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. (2023/01/01) ♡
• Epidemiological Impact of Neurodegenerative Diseases in the Rural Spanish-Portuguese Cross-Border Region. (2023/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Cerebral Tau Deposition in Comorbid Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis: An [18F]-Flortaucipir and 7T MRI Study. (2023/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (2023-12-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS (2023-12-04) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Phase II Clinical Trial of OCH-NCNP1 (2023-11-09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation (2023-11-08) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis (2023-10-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Novel Imaging Markers in SPMS (2023-09-26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 (2023-09-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study (2023-08-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). (2023-07-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Osmotin Plant Protein for Progressive Multiple Sclerosis (2023-07-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) (2023-07-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden (2023-06-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of Diroximel Fumarate in the Real-World Setting (2023-05-26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (2023-05-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis (2023-05-09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis (2023-05-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo (2023-04-24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis (2023-03-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis (2023-02-06) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (2023-01-30) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multiple Sclerosis Impact on Pregnancy: An Update on Management Issues : Management of MS During Pregnancy. (2022/12/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Extracellular Vesicles in Amyotrophic Lateral Sclerosis. (2022/12/31) ♡
• Making Visible the Invisible: Automatically Measured Global and Regional Brain Volume Is Associated with Cognitive Impairment and Fatigue in Multiple Sclerosis. (2022/12/29) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.